SECOND GENERATION ANTIPSYCHOTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Second Generation Antipsychotics Market is estimated to be valued at USD 10.25 Bn in 2025 and is expected to reach USD 15.67 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.25% from 2025 to 2032. The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

• This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global second generation antipsychotics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

•  Indication Insights (Revenue, USD Bn, 2020 - 2032)
• • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Autism Spectrum Disorder
  • Other Indications
•  Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
• • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Asenapine
  • Clozapine
  • Paliperidone
  • Brexpiprazole
  • Lurasidone
  • Others
•  Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• • Oral
  • Parenteral
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Otsuka Pharmaceutical
  • Lundbeck
  • Sanofi
  • Merck & Co.
  • AbbVie
  • Takeda Pharmaceutical
  • Amgen
  • GlaxoSmithKline
  • Alkermes